C. elegans as model for the study of high glucose-mediated life span reduction

Andreas Schlotterer, Georgi Kukudov, Farastuk Bozorgmehr, Harald Hutter, Xueliang Du, Dimitrios Oikonomou, Youssef Ibrahim, Friederike Pfisterer, Naila Rabbani, Paul Thornalley, Ahmed Sayed, Thomas Fleming, Per Humpert, Vedat Schwenger, Martin Zeier, Andreas Hamann, David Stern, Michael Brownlee, Angelika Bierhaus, Peter NawrothMichael Morcos

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

OBJECTIVE - Establishing Caenorhabditis elegans as a model for glucose toxicity-mediated life span reduction. RESEARCH DESIGN AND METHODS - C. elegans were maintained to achieve glucose concentrations resembling the hyperglycemic conditions in diabetic patients. The effects of high glucose on life span, glyoxalase-1 activity, advanced glycation end products (AGEs), and reactive oxygen species (ROS) formation and on mitochondrial function were studied. RESULTS - High glucose conditions reduced mean life span from 18.5 ± 0.4 to 16.5 ± 0.6 days and maximum life span from 25.9 ± 0.4 to 23.2 ± 0.4 days, independent of glucose effects on cuticle or bacterial metabolization of glucose. The formation of methylglyoxal-modified mitochondrial proteins and ROS was significantly increased by high glucose conditions and reduced by mitochondrial uncoupling and complex IIIQo inhibition. Overexpression of the methylglyoxal- detoxifying enzyme glyoxalase-1 attenuated the life-shortening effect of glucose by reducing AGE accumulation (by 65%) and ROS formation (by 50%) and restored mean (16.5 ± 0.6 to 20.6 ± 0.4 days) and maximum life span (23.2 ± 0.4 to 27.7 ± 2.3 days). In contrast, inhibition of glyoxalase-1 by RNAi further reduced mean (16.5 ± 0.6 to 13.9 ± 0.7 days) and maximum life span (23.2 ± 0.4 to 20.3 ± 1.1 days). The life span reduction by glyoxalase-1 inhibition was independent from the insulin signaling pathway because high glucose conditions also affected daf-2 knockdown animals in a similar manner. CONCLUSIONS - C. elegans is a suitable model organism to study glucose toxicity, in which high glucose conditions limit the life span by increasing ROS formation and AGE modification of mitochondrial proteins in a daf-2 independent manner. Most importantly, glucose toxicity can be prevented by improving glyoxalase-1- dependent methylglyoxal detoxification or preventing mitochondrial dysfunction.

Original languageEnglish (US)
Pages (from-to)2450-2456
Number of pages7
JournalDiabetes
Volume58
Issue number11
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Glucose
Pyruvaldehyde
Reactive Oxygen Species
Caenorhabditis elegans
Mitochondrial Proteins
Advanced Glycosylation End Products
RNA Interference
Research Design
Insulin
Enzymes

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Schlotterer, A., Kukudov, G., Bozorgmehr, F., Hutter, H., Du, X., Oikonomou, D., ... Morcos, M. (2009). C. elegans as model for the study of high glucose-mediated life span reduction. Diabetes, 58(11), 2450-2456. https://doi.org/10.2337/db09-0567

C. elegans as model for the study of high glucose-mediated life span reduction. / Schlotterer, Andreas; Kukudov, Georgi; Bozorgmehr, Farastuk; Hutter, Harald; Du, Xueliang; Oikonomou, Dimitrios; Ibrahim, Youssef; Pfisterer, Friederike; Rabbani, Naila; Thornalley, Paul; Sayed, Ahmed; Fleming, Thomas; Humpert, Per; Schwenger, Vedat; Zeier, Martin; Hamann, Andreas; Stern, David; Brownlee, Michael; Bierhaus, Angelika; Nawroth, Peter; Morcos, Michael.

In: Diabetes, Vol. 58, No. 11, 01.11.2009, p. 2450-2456.

Research output: Contribution to journalArticle

Schlotterer, A, Kukudov, G, Bozorgmehr, F, Hutter, H, Du, X, Oikonomou, D, Ibrahim, Y, Pfisterer, F, Rabbani, N, Thornalley, P, Sayed, A, Fleming, T, Humpert, P, Schwenger, V, Zeier, M, Hamann, A, Stern, D, Brownlee, M, Bierhaus, A, Nawroth, P & Morcos, M 2009, 'C. elegans as model for the study of high glucose-mediated life span reduction', Diabetes, vol. 58, no. 11, pp. 2450-2456. https://doi.org/10.2337/db09-0567
Schlotterer A, Kukudov G, Bozorgmehr F, Hutter H, Du X, Oikonomou D et al. C. elegans as model for the study of high glucose-mediated life span reduction. Diabetes. 2009 Nov 1;58(11):2450-2456. https://doi.org/10.2337/db09-0567
Schlotterer, Andreas ; Kukudov, Georgi ; Bozorgmehr, Farastuk ; Hutter, Harald ; Du, Xueliang ; Oikonomou, Dimitrios ; Ibrahim, Youssef ; Pfisterer, Friederike ; Rabbani, Naila ; Thornalley, Paul ; Sayed, Ahmed ; Fleming, Thomas ; Humpert, Per ; Schwenger, Vedat ; Zeier, Martin ; Hamann, Andreas ; Stern, David ; Brownlee, Michael ; Bierhaus, Angelika ; Nawroth, Peter ; Morcos, Michael. / C. elegans as model for the study of high glucose-mediated life span reduction. In: Diabetes. 2009 ; Vol. 58, No. 11. pp. 2450-2456.
@article{14cd77c9b8ed4989a8354ba9da6462ff,
title = "C. elegans as model for the study of high glucose-mediated life span reduction",
abstract = "OBJECTIVE - Establishing Caenorhabditis elegans as a model for glucose toxicity-mediated life span reduction. RESEARCH DESIGN AND METHODS - C. elegans were maintained to achieve glucose concentrations resembling the hyperglycemic conditions in diabetic patients. The effects of high glucose on life span, glyoxalase-1 activity, advanced glycation end products (AGEs), and reactive oxygen species (ROS) formation and on mitochondrial function were studied. RESULTS - High glucose conditions reduced mean life span from 18.5 ± 0.4 to 16.5 ± 0.6 days and maximum life span from 25.9 ± 0.4 to 23.2 ± 0.4 days, independent of glucose effects on cuticle or bacterial metabolization of glucose. The formation of methylglyoxal-modified mitochondrial proteins and ROS was significantly increased by high glucose conditions and reduced by mitochondrial uncoupling and complex IIIQo inhibition. Overexpression of the methylglyoxal- detoxifying enzyme glyoxalase-1 attenuated the life-shortening effect of glucose by reducing AGE accumulation (by 65{\%}) and ROS formation (by 50{\%}) and restored mean (16.5 ± 0.6 to 20.6 ± 0.4 days) and maximum life span (23.2 ± 0.4 to 27.7 ± 2.3 days). In contrast, inhibition of glyoxalase-1 by RNAi further reduced mean (16.5 ± 0.6 to 13.9 ± 0.7 days) and maximum life span (23.2 ± 0.4 to 20.3 ± 1.1 days). The life span reduction by glyoxalase-1 inhibition was independent from the insulin signaling pathway because high glucose conditions also affected daf-2 knockdown animals in a similar manner. CONCLUSIONS - C. elegans is a suitable model organism to study glucose toxicity, in which high glucose conditions limit the life span by increasing ROS formation and AGE modification of mitochondrial proteins in a daf-2 independent manner. Most importantly, glucose toxicity can be prevented by improving glyoxalase-1- dependent methylglyoxal detoxification or preventing mitochondrial dysfunction.",
author = "Andreas Schlotterer and Georgi Kukudov and Farastuk Bozorgmehr and Harald Hutter and Xueliang Du and Dimitrios Oikonomou and Youssef Ibrahim and Friederike Pfisterer and Naila Rabbani and Paul Thornalley and Ahmed Sayed and Thomas Fleming and Per Humpert and Vedat Schwenger and Martin Zeier and Andreas Hamann and David Stern and Michael Brownlee and Angelika Bierhaus and Peter Nawroth and Michael Morcos",
year = "2009",
month = "11",
day = "1",
doi = "10.2337/db09-0567",
language = "English (US)",
volume = "58",
pages = "2450--2456",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - C. elegans as model for the study of high glucose-mediated life span reduction

AU - Schlotterer, Andreas

AU - Kukudov, Georgi

AU - Bozorgmehr, Farastuk

AU - Hutter, Harald

AU - Du, Xueliang

AU - Oikonomou, Dimitrios

AU - Ibrahim, Youssef

AU - Pfisterer, Friederike

AU - Rabbani, Naila

AU - Thornalley, Paul

AU - Sayed, Ahmed

AU - Fleming, Thomas

AU - Humpert, Per

AU - Schwenger, Vedat

AU - Zeier, Martin

AU - Hamann, Andreas

AU - Stern, David

AU - Brownlee, Michael

AU - Bierhaus, Angelika

AU - Nawroth, Peter

AU - Morcos, Michael

PY - 2009/11/1

Y1 - 2009/11/1

N2 - OBJECTIVE - Establishing Caenorhabditis elegans as a model for glucose toxicity-mediated life span reduction. RESEARCH DESIGN AND METHODS - C. elegans were maintained to achieve glucose concentrations resembling the hyperglycemic conditions in diabetic patients. The effects of high glucose on life span, glyoxalase-1 activity, advanced glycation end products (AGEs), and reactive oxygen species (ROS) formation and on mitochondrial function were studied. RESULTS - High glucose conditions reduced mean life span from 18.5 ± 0.4 to 16.5 ± 0.6 days and maximum life span from 25.9 ± 0.4 to 23.2 ± 0.4 days, independent of glucose effects on cuticle or bacterial metabolization of glucose. The formation of methylglyoxal-modified mitochondrial proteins and ROS was significantly increased by high glucose conditions and reduced by mitochondrial uncoupling and complex IIIQo inhibition. Overexpression of the methylglyoxal- detoxifying enzyme glyoxalase-1 attenuated the life-shortening effect of glucose by reducing AGE accumulation (by 65%) and ROS formation (by 50%) and restored mean (16.5 ± 0.6 to 20.6 ± 0.4 days) and maximum life span (23.2 ± 0.4 to 27.7 ± 2.3 days). In contrast, inhibition of glyoxalase-1 by RNAi further reduced mean (16.5 ± 0.6 to 13.9 ± 0.7 days) and maximum life span (23.2 ± 0.4 to 20.3 ± 1.1 days). The life span reduction by glyoxalase-1 inhibition was independent from the insulin signaling pathway because high glucose conditions also affected daf-2 knockdown animals in a similar manner. CONCLUSIONS - C. elegans is a suitable model organism to study glucose toxicity, in which high glucose conditions limit the life span by increasing ROS formation and AGE modification of mitochondrial proteins in a daf-2 independent manner. Most importantly, glucose toxicity can be prevented by improving glyoxalase-1- dependent methylglyoxal detoxification or preventing mitochondrial dysfunction.

AB - OBJECTIVE - Establishing Caenorhabditis elegans as a model for glucose toxicity-mediated life span reduction. RESEARCH DESIGN AND METHODS - C. elegans were maintained to achieve glucose concentrations resembling the hyperglycemic conditions in diabetic patients. The effects of high glucose on life span, glyoxalase-1 activity, advanced glycation end products (AGEs), and reactive oxygen species (ROS) formation and on mitochondrial function were studied. RESULTS - High glucose conditions reduced mean life span from 18.5 ± 0.4 to 16.5 ± 0.6 days and maximum life span from 25.9 ± 0.4 to 23.2 ± 0.4 days, independent of glucose effects on cuticle or bacterial metabolization of glucose. The formation of methylglyoxal-modified mitochondrial proteins and ROS was significantly increased by high glucose conditions and reduced by mitochondrial uncoupling and complex IIIQo inhibition. Overexpression of the methylglyoxal- detoxifying enzyme glyoxalase-1 attenuated the life-shortening effect of glucose by reducing AGE accumulation (by 65%) and ROS formation (by 50%) and restored mean (16.5 ± 0.6 to 20.6 ± 0.4 days) and maximum life span (23.2 ± 0.4 to 27.7 ± 2.3 days). In contrast, inhibition of glyoxalase-1 by RNAi further reduced mean (16.5 ± 0.6 to 13.9 ± 0.7 days) and maximum life span (23.2 ± 0.4 to 20.3 ± 1.1 days). The life span reduction by glyoxalase-1 inhibition was independent from the insulin signaling pathway because high glucose conditions also affected daf-2 knockdown animals in a similar manner. CONCLUSIONS - C. elegans is a suitable model organism to study glucose toxicity, in which high glucose conditions limit the life span by increasing ROS formation and AGE modification of mitochondrial proteins in a daf-2 independent manner. Most importantly, glucose toxicity can be prevented by improving glyoxalase-1- dependent methylglyoxal detoxification or preventing mitochondrial dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=70350365865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350365865&partnerID=8YFLogxK

U2 - 10.2337/db09-0567

DO - 10.2337/db09-0567

M3 - Article

C2 - 19675139

AN - SCOPUS:70350365865

VL - 58

SP - 2450

EP - 2456

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -